mTOR抑制剂依维莫司联合[177Lu]Lu-DOTA-TATE肽受体放射性核素治疗在Lewis大鼠中的毒性研究
在雌性Lewis大鼠中比较安慰剂、依维莫司单药、[177Lu]Lu-DOTA-TATE单药及两者联合的毒性;结果显示依维莫司联合PRRT不增加PRRT的肾脏和血液学毒性,肾闪烁显像对联合治疗后肾功能损害的检测高度敏感。
要点
- 依维莫司联合[177Lu]Lu-DOTA-TATE未增加PRRT的肾脏和血液学毒性。
- 依维莫司组肌酐升高幅度显著低于安慰剂组。
- 肾闪烁显像可敏感检出联合治疗后的肾功能损害。
核心结论
- 肾闪烁显像对检测依维莫司联合PRRT后的肾功能损害高度敏感。
- 额外给予依维莫司不增加[177Lu]Lu-DOTA-TATE PRRT的肾脏和血液学毒性。
研究设计与样本
- 雌性Lewis大鼠分为四组:组1安慰剂、组2依维莫司、组3安慰剂+[177Lu]Lu-DOTA-TATE、组4依维莫司+[177Lu]Lu-DOTA-TATE。
- 动物接受200 MBq [177Lu]Lu-DOTA-TATE一次和/或5 mg/kg体重依维莫司或安慰剂每周一次共16周。
- 每周检测肌酐和血尿素氮水平,安乐死时行全血细胞计数,并系列行[99mTc]Tc-MAG3肾闪烁显像。
- 所有肾脏行组织病理学检查,采用标准化肾损伤评分(RDS)。
主要发现
- 接受依维莫司的大鼠肌酐水平升高幅度显著低于接受安慰剂的大鼠。
- 依维莫司治疗显著降低白细胞计数,而[177Lu]Lu-DOTA-TATE未观察到该现象。
- [99mTc]Tc-MAG3功能肾闪烁显像显示PRRT后初始示踪剂摄取受损,依维莫司后排泄较慢但仍保留。
- 组织学显示各组间RDS无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA0,TYR3-octreotate ([177Lu]Lu-DOTA-TATE) and the mechanistic target of rapamycin (mTOR) inhibitor everolimus are both approved for the treatment of neuroendocrine tumours (NET). However, tumour progression is still frequent, and treatment strategies need further improvement. One possible approach could be to combine different therapy options. In this study, we investigated the toxicity of a combined treatment with everolimus and [177Lu]Lu-DOTA-TATE in female Lewis rats. METHODS: Animals received 200 MBq of [177Lu]Lu-DOTA-TATE once and/or 5 mg/kg body weight everolimus or placebo weekly for 16 weeks and were divided into four groups (group 1, placebo; group 2, everolimus; group 3, placebo + [177Lu]Lu-DOTA-TATE; group 4, everolimus + [177Lu]Lu-DOTA-TATE). Blood levels of creatinine and blood urea nitrogen (BUN) were assessed weekly to monitor nephrotoxicity, and a full blood count was performed at the time of euthanasia to monitor myelotoxicity. Additionally, renal function was analysed by sequential [99mTc]Tc-mercaptoacetyltriglycine ([99mTc]Tc-MAG3) scintigraphies. Histopathological examination was performed in all the kidneys using a standardized renal damage score (RDS). RESULTS: Rats receiving everolimus showed a significantly lower increase in creatinine levels than those receiving placebo. Everolimus therapy reduced white blood count significantly, which was not observed for [177Lu]Lu-DOTA-TATE. Functional renal scintigraphies using [99mTc]Tc-MAG3 showed a compromised initial tracer uptake after PRRT and slower but still preserved excretion after everolimus. Histology showed no significant RDS differences between groups. CONCLUSION: Renal scintigraphy is a highly sensitive tool for the detection of renal function impairment after a combination of everolimus and PRRT. Additional treatment with everolimus does not increase renal and haematological toxicity of PRRT with [177Lu]Lu-DOTA-TATE.
引用
- Zellmer J, Yen HY, Kaiser L, et al. Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats. EJNMMI Res. 2020. PMID: 32335736. doi:10.1186/s13550-020-00628-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。